A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat

Objective: We report the results of pharmacogenomics-based antidepressant treatment (PGXt) results in treating treatment-resistant major depressive disorder (TRD) patients in real practice. Methods: Nine patients were prescribed Neuropharmagen (R) for selection of antidepressants for individual patient and their clinical outcomes were followed. Results: After treatment by PGXt results from current antidepressants, substantial reduction of depressive symptoms was observed at some point and maintained during observation period in six patients. Conclusion: Our case series potentially shows the clinical utility and benefit of PGXt for treatment of TRD patients.

Automated summary

This study reports the results of pharmacogenomics-based antidepressant treatment in treatment-resistant major depressive disorder patients, demonstrating the clinical utility and benefit of PGXt in reducing depressive symptoms in some patients.